Jan 19th, 2026
Closing Main Event
Research will be presented from eight pivotal trials, including SPAN2, CONCERN and DISTALS.
11 a.m.-1:25 p.m. | Main Event 3
Plan to stay for the Closing Session, which will offer the Ralph L. Sacco Outstanding Stroke Research Mentor Award, the Sherman Lecture, the Stroke Council Award, and the results from these randomized clinical trials.
- Final Results of the SPAN2 Trial
- The I-ACQUIRE Trial of Constraint Induced Movement Therapy for Infants/Toddlers With Perinatal Arterial Ischemic Stroke
- Loberamisal for Acute Ischaemic Stroke (LAIS): A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase 3 Clinical Trial
- LT3001 Improves Functional Outcomes in Disabling Acute Ischemic Stroke: Results From Two Phase 2 Trials
- Efficacy and Safety of Chuanzhi Tongluo Capsule for Acute Ischemic Stroke Patients Without Large or Medium-Sized Vessel Occlusion (CONCERN): A Multicenter Double-Blind Randomized Control Trial
- Endovascular Treatment of Medium Vessel Occlusion Strokes With Moderate or Higher Clinical Severity
- Primary Results of the DISTALS (Distal Ischemic Stroke Treatment With Adjustable Low-Profile Stentriever) Randomized Trial of TIGERTRIEVER 13-EVT for DMVO
- A Randomized Trial of an At-Home Brain Computer Interface Therapy Compared To Standard Exercise Therapy For Chronic Upper Extremity Motor Deficit After Stroke
